NCT06539208招募中1 期
A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
YolTech Therapeutics Co., Ltd3 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2024年5月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 31
- 试验地点
- 3
- 主要终点
- Safety and Tolerability
研究概览
简要总结
This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of YOLT-201 in participants with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 - 80 years old (including the critical values), regardless of gender;
- •Body weight at the time of screening is between 40 - 90kg (including the critical values);
- •TTR gene mutation is confirmed by genetic testing;
- •At the time of screening, the following laboratory standards must be met:
- •AST, ALT, and TBIL ≤ the upper limit of the normal value (ULN);
- •For subjects with Gilbert syndrome, TBIL ≤ 2 times ULN;
- •Glomerular filtration rate (GFR) ≥ 45 mL/min/1.73m2 (calculated according to the CKD-EPI formula);
- •Platelet count ≥ 100 × 109/L;
- •Partial thromboplastin time (APTT), prothrombin time (PT), and thrombin generation time (TGT) are all within the reference value range, fibrinogen (FIB) ≥ the lower limit of the normal value (LLN) and ≤ 1.5*ULN, the international normalized ratio (INR) ≤ ULN, and if taking anticoagulant drugs, it is ≤ 2.5*ULN;
- •Vitamin A and vitamin B12 ≥ the lower limit of the reference value (LLN);
- •Low-density lipoprotein cholesterol (LDL) < 200 mg/dL (5.17 mmol/L).
- •Drugs approved for the treatment of ATTR are not accessible (Criterion A) and/or the disease still progresses despite the use of drugs approved for the treatment of ATTR (Criterion B):
- •Criterion A: Meeting one or more of the following criteria:
- •Drugs for the treatment of ATTR are not marketed in China;
- •Unable to receive the approved drugs for ATTR treatment (e.g., intolerance or other medical, cost and/or other reasons);
- •Criterion B: Subjects have received ATTR drug treatment for at least 3 months, but the subject's condition has progressed as assessed by the investigator, and meets any of the following criteria:
- •ATTR-CM: a. Increased number of hospitalizations related to heart failure; b. Worsening of NYHA classification; c. Decrease in KCCQ score by at least 5 points; d. Decrease in 6-MWT by at least 30m; e. Increase in NT-proBNP by 30%; f. Increase in Troponin I by 30%; g. Echocardiography indicates an increase in left ventricular wall thickness by 2mm; h. Echocardiography indicates a decrease in left ventricular ejection fraction by ≥ 5% or a decrease in global longitudinal strain by ≥ 1% or a decrease in stroke volume by ≥ 5%; i. New conduction block appears; ATTR-PN: a. PND score increase by ≥ 1 point; b. FAP increases by 1 stage; c. NIS score increase by ≥ 5 points; d. NIS-Lower Limb score increase by ≥ 5 points; e. mBMI decrease by ≥ 25 kg/m2×g/L; f. 10-MWT decrease by ≥ 0.1 m/s; g. Electroneurophysiological examination (electromyography) worsens compared to the previous.
- •Agree to stop drinking alcohol within the screening period to 28 days after administration;
- •Female subjects need to be menopausal (absence of menstruation for at least 1 year) or have undergone uterine/ovarian resection surgery; Male subjects and their partners have no fertility plans from the screening period to 6 months after the end of the trial and agree to take effective non-pharmaceutical contraceptive measures during the trial;
- •The subject himself/herself (or his/her legally recognized representative) understands and signs the informed consent form;
- •Agree not to receive other ATTR drug intervention treatment within at least 8 weeks after administration of YOLT-201;
- •For ATTR-PN only:
- •Diagnosed as ATTR-PN according to the "Consensus on the Diagnosis and Treatment of Transthyretin Amyloidosis Polyneuropathy", and the NIS score at the screening is ≥ 5 and ≤ 130, and the PND score is ≤ IIIb;
- •NT-proBNP < 600pg/ml at the screening;
- •For ATTR-CM only:
- •Diagnosed as ATTR-CM according to the "Expert Consensus on the Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis";
- •The New York Heart Association (NYHA) cardiac function classification is grade II - III;
- •The 6-minute walk test (6-MWT) is ≥ 150 m at the screening;
- •NT-proBNP is ≥ 600pg/mL and ≤ 3000pg/mL at the screening;
- •At the screening, echocardiography suggests evidence of cardiac involvement: the thickness of the interventricular septum and/or the posterior wall of the left ventricle is ≥ 12 mm.
排除标准
- •Amyloidosis is not caused by TTR protein, such as light chain amyloidosis;
- •There is meningeal transthyretin amyloidosis;
- •Allergic to any lipid nanoparticle (LNP) component or has previously received LNP and experienced treatment-related laboratory abnormalities or adverse events;
- •Use any of the following ATTR treatments within the prescribed time:
- •In the dose escalation stage of the first stage, the use history of Patisiran, Inotersen, and Vutrisiran is excluded;
- •In the dose expansion stage of the second stage, the following are excluded: Patisiran is used within 90 days before the administration of the investigational drug; Inotersen is used within 160 days before the administration of the investigational drug; Vutrisiran has a previous use history;
- •Tafamidis: used within 10 days before the administration of the investigational drug;
- •Diflunisal: used within 3 days before the administration of the investigational drug;
- •Doxycycline and/or taurodeoxycholic acid: used within 14 days before the administration of the investigational drug;
- •Previous use history of investigational gene editing drugs;
- •Other drugs for the treatment of ATTR: the last use is less than 30 days or 5 half-lives before the administration of the investigational drug, whichever is longer.
- •Unable or unwilling to supplement vitamin A during the trial;
- •History of multiple myeloma;
- •Ophthalmological examination results at the screening are consistent with vitamin A deficiency;
- •Abnormal thyroid function test with clinical significance judged by the investigator;
- •Known or suspected systemic infection (viral, parasitic or fungal infection) within 14 days before screening;
- •History of past hepatitis B virus, hepatitis C virus, acquired immunodeficiency syndrome or positive HBsAg, HCV-Ab, and HIV-Ab at the screening;
- •History of previous liver, heart or other organ transplantation or bone marrow transplantation or expected transplantation within 1 year (except for the history of corneal transplantation or planned corneal transplantation);
- •History of bleeding or coagulation disorders (such as cirrhosis, malignant hematological disease, antiphospholipid antibody syndrome);
- •History of acute thrombosis within 6 months before screening (such as acute myocardial infarction, acute cerebral infarction), or positive Leiden factor V and/or prothrombin gene test;
- •History of malignant tumor within 5 years before screening (except for basal cell carcinoma of the skin, radicalized squamous cell carcinoma of the skin, and carcinoma in situ of the cervix);
- •Planned invasive cardiovascular surgery during the trial (such as coronary artery stent/coronary artery bypass, pacemaker placement, etc.); those who have undergone cardiovascular invasive surgery within 90 days before screening or have been hospitalized due to heart failure;
- •History of alcohol abuse within 3 years before screening (definition of alcohol abuse: women drink ≥ 4 glasses/day or 8 glasses/week, men ≥ 5 glasses or 15 glasses/week, where 1 glass = 14g of pure alcohol);
- •Expected survival period is less than 1 year;
- •Other situations that the investigator deems inappropriate to enter this trial;
- •For ATTR-PN only:
- •Other known diseases that cause motor or sensory neuropathy (such as diabetic neuropathy, neuropathy related to autoimmune diseases, etc.);
- •Diagnosed with type 1 diabetes or type 2 diabetes for ≥ 5 years;
- •NYHA cardiac function classification is grade III or IV within 90 days before screening;
- •For ATTR-CM only:
- •NYHA cardiac function classification is grade IV within 90 days before screening;
- •PND score is grade IIIa, IIIb or IV at the screening;
- •Suffering from other cardiomyopathies not caused by TTR (such as hypertensive cardiomyopathy, valvular heart disease, cardiomyopathy caused by ischemic heart disease, etc.).
研究组 & 干预措施
YOLT-201
Experimental
干预措施: YOLT-201 (Drug)
结局指标
主要结局
Safety and Tolerability
时间窗: through week 104
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)NCT04601051Intellia Therapeutics72
已完成
1 期
Study of SIAN Nasal Spray in Healthy AdultsCyanide PoisoningNCT05194358Emergent BioSolutions47
已完成
1 期
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy VolunteersHerpes Simplex Virus InfectionNCT02346760United BioPharma15
已完成
1 期
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult ParticipantsHIV InfectionsNCT06033547ViiV Healthcare56
已完成
1 期
Study of M5049 in Healthy Japanese and Caucasian ParticipantsHealthyNCT04880213Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany36